A building on the campus at the world headquarters of Illumina is shown in San Diego, California, Sept. 1, 2021.
Mike Blake | Reuters
The U.S. Securities and Exchange Commission is investigating Illumina over its controversial $7.1 billion acquisition of cancer test developer Grail, the DNA sequencing company said in a securities filing late Thursday.
Last month, the SEC informed Illumina about the probe and requested documents and communications related to the deal. The agency also asked for statements and disclosures about the ”conduct and compensation” of certain members of both Illumina and Grail’s management, according to the filing.
Illumina, in the filing, said it is cooperating with the SEC. An agency spokesperson did not immediately respond to CNBC’s request for comment on the investigation.
Shares of Illumina fell about 4% Friday.
The SEC’s probe only puts more pressure on Illumina, which has lost great sums of money since closing the deal in August 2021. The company’s…
2023-08-11 14:52:30
Post from www.cnbc.com